Cargando…

Fetal hemoglobin level and nutritional status in patients with sickle cell disease

Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is importa...

Descripción completa

Detalles Bibliográficos
Autor principal: Badawy, Sherif M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939000/
https://www.ncbi.nlm.nih.gov/pubmed/27390841
http://dx.doi.org/10.1186/s12937-016-0181-x
_version_ 1782441943027941376
author Badawy, Sherif M.
author_facet Badawy, Sherif M.
author_sort Badawy, Sherif M.
collection PubMed
description Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients’ nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age.
format Online
Article
Text
id pubmed-4939000
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49390002016-07-10 Fetal hemoglobin level and nutritional status in patients with sickle cell disease Badawy, Sherif M. Nutr J Letter to the Editor Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients’ nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age. BioMed Central 2016-07-08 /pmc/articles/PMC4939000/ /pubmed/27390841 http://dx.doi.org/10.1186/s12937-016-0181-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Badawy, Sherif M.
Fetal hemoglobin level and nutritional status in patients with sickle cell disease
title Fetal hemoglobin level and nutritional status in patients with sickle cell disease
title_full Fetal hemoglobin level and nutritional status in patients with sickle cell disease
title_fullStr Fetal hemoglobin level and nutritional status in patients with sickle cell disease
title_full_unstemmed Fetal hemoglobin level and nutritional status in patients with sickle cell disease
title_short Fetal hemoglobin level and nutritional status in patients with sickle cell disease
title_sort fetal hemoglobin level and nutritional status in patients with sickle cell disease
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939000/
https://www.ncbi.nlm.nih.gov/pubmed/27390841
http://dx.doi.org/10.1186/s12937-016-0181-x
work_keys_str_mv AT badawysherifm fetalhemoglobinlevelandnutritionalstatusinpatientswithsicklecelldisease